JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Accueil・Liste d'Actions・Puma Biotechnology Inc
Search

Puma Biotechnology Inc

Fermé

SecteurSoins de santé

7.44 -0.67

Neutre

Actualisation du prix 1 mai 2026, 19:59 UTC

AcheterVendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.44

Max

7.5

Chiffres clés

By Trading Economics

Revenu

3M

12M

Ventes

21M

76M

P/E

Moyenne du Secteur

12.312

67.147

Marge bénéficiaire

15.633

Employés

179

EBITDA

13M

27M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

-33.24% downside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

24M

382M

Ouverture précédente

8.11

Clôture précédente

7.44

Sentiment de l'Actualité

By Acuity

50%

50%

176 / 347 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

3.07 / 3.075 Support & Résistance

Puma Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 mai 2026, 22:17 UTC

Résultats

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Lire

4 mai 2026, 23:47 UTC

Résultats

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Lire

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Lire

4 mai 2026, 23:45 UTC

Résultats

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Lire

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Lire

4 mai 2026, 22:44 UTC

Acquisitions, Fusions, Rachats

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Lire

4 mai 2026, 22:43 UTC

Acquisitions, Fusions, Rachats

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Lire

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Lire

4 mai 2026, 22:42 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Lire

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Lire

4 mai 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Shareholders to Own About 51% of Combined Company

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Lire

4 mai 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Regis: Deal Unanimously Recommended by Vault Board

DJ

Lire

4 mai 2026, 22:39 UTC

Acquisitions, Fusions, Rachats

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Lire

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Lire

4 mai 2026, 22:38 UTC

Acquisitions, Fusions, Rachats

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Lire

4 mai 2026, 22:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Lire

4 mai 2026, 22:26 UTC

Résultats
Acquisitions, Fusions, Rachats

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Lire

4 mai 2026, 22:02 UTC

Résultats

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Lire

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Lire

4 mai 2026, 21:52 UTC

Résultats

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Lire

4 mai 2026, 21:50 UTC

Résultats

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Lire

4 mai 2026, 21:50 UTC

Résultats

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Lire

4 mai 2026, 21:49 UTC

Résultats

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Lire

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Lire

4 mai 2026, 21:44 UTC

Résultats

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Lire

4 mai 2026, 21:43 UTC

Résultats

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Lire

4 mai 2026, 21:41 UTC

Résultats

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Lire

4 mai 2026, 21:40 UTC

Résultats

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Lire

Comparaison

Variation de prix

Puma Biotechnology Inc prévision

Objectif de Prix

By TipRanks

-33.24% baisse

Prévisions sur 12 Mois

Moyen 5 USD  -33.24%

Haut 5 USD

Bas 5 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

1 ratings

0

Achat

1

Maintien

0

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

3.07 / 3.075Support & Résistance

Court Terme

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Moyen Terme

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Long Terme

Bullish Evidence

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

176 / 347Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Autres valeurs du secteur

JNJ

Johnson and Johnson

224.16

↓-1.45%

UNH

UnitedHealth Group Inc

370.76

↑ +0.47%

TMO

Thermo Fisher Scientific Inc

462.35

↓-1.48%

ISRG

Intuitive Surgical Inc

452.39

↓-1.14%

ABT

Abbott Laboratories

87.56

↓-2.18%
help-icon Live chat